These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 26729494

  • 1. Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam-β-Lactamase Inhibitor Combinations.
    Soon RL, Lenhard JR, Bulman ZP, Holden PN, Kelchlin P, Steenbergen JN, Friedrich LV, Forrest A, Tsuji BT.
    Antimicrob Agents Chemother; 2016 Apr; 60(4):1967-73. PubMed ID: 26729494
    [Abstract] [Full Text] [Related]

  • 2. Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection.
    MacGowan AP, Noel AR, Tomaselli SG, Nicholls D, Bowker KE.
    Antimicrob Agents Chemother; 2016 Jan; 60(1):515-21. PubMed ID: 26552975
    [Abstract] [Full Text] [Related]

  • 3. In vitro pharmacodynamic evaluation of ceftolozane/tazobactam against β-lactamase-producing Escherichia coli in a hollow-fibre infection model.
    Soon RL, Lenhard JR, Bulman ZP, Holden PN, Kelchlin P, Steenbergen JN, Friedrich LV, Forrest A, Tsuji BT.
    Int J Antimicrob Agents; 2017 Jan; 49(1):25-30. PubMed ID: 27931793
    [Abstract] [Full Text] [Related]

  • 4. Pharmacological basis of β-lactamase inhibitor therapeutics: tazobactam in combination with Ceftolozane.
    Vanscoy B, Mendes RE, McCauley J, Bhavnani SM, Bulik CC, Okusanya OO, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG.
    Antimicrob Agents Chemother; 2013 Dec; 57(12):5924-30. PubMed ID: 24041895
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model.
    Nicasio AM, VanScoy BD, Mendes RE, Castanheira M, Bulik CC, Okusanya OO, Bhavnani SM, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG.
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2075-80. PubMed ID: 26787689
    [Abstract] [Full Text] [Related]

  • 6. Pharmacodynamics of Ceftolozane Combined with Tazobactam against Enterobacteriaceae in a Neutropenic Mouse Thigh Model.
    Melchers MJ, Mavridou E, van Mil AC, Lagarde C, Mouton JW.
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7272-7279. PubMed ID: 27671063
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. In Vitro Activity of Ceftolozane Alone and in Combination with Tazobactam against Extended-Spectrum-β-Lactamase-Harboring Enterobacteriaceae.
    Melchers MJ, van Mil AC, Mouton JW.
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4521-5. PubMed ID: 25987635
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).
    Sader HS, Farrell DJ, Flamm RK, Jones RN.
    J Infect; 2014 Sep; 69(3):266-77. PubMed ID: 24780763
    [Abstract] [Full Text] [Related]

  • 11. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
    Zhanel GG, Chung P, Adam H, Zelenitsky S, Denisuik A, Schweizer F, Lagacé-Wiens PR, Rubinstein E, Gin AS, Walkty A, Hoban DJ, Lynch JP, Karlowsky JA.
    Drugs; 2014 Jan; 74(1):31-51. PubMed ID: 24352909
    [Abstract] [Full Text] [Related]

  • 12. Post-β-lactamase-inhibitor effect of tazobactam in combination with ceftolozane on extended-spectrum-β-lactamase-producing strains.
    Sader HS, Rhomberg PR, Jones RN.
    Antimicrob Agents Chemother; 2014 Jan; 58(4):2434-7. PubMed ID: 24449780
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa.
    Barnes MD, Taracila MA, Rutter JD, Bethel CR, Galdadas I, Hujer AM, Caselli E, Prati F, Dekker JP, Papp-Wallace KM, Haider S, Bonomo RA.
    mBio; 2018 Dec 11; 9(6):. PubMed ID: 30538183
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study.
    Tato M, García-Castillo M, Bofarull AM, Cantón R, CENIT Study Group.
    Int J Antimicrob Agents; 2015 Nov 11; 46(5):502-10. PubMed ID: 26315199
    [Abstract] [Full Text] [Related]

  • 18. Exploring the effectiveness of tazobactam against ceftazidime resistant Escherichia coli: insights from the comparison between susceptibility testing and beta-lactamase inhibition.
    Bethel CR, Hujer AM, Helfand MS, Bonomo RA.
    FEMS Microbiol Lett; 2004 May 01; 234(1):99-103. PubMed ID: 15109726
    [Abstract] [Full Text] [Related]

  • 19. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
    Sader HS, Farrell DJ, Castanheira M, Flamm RK, Jones RN.
    J Antimicrob Chemother; 2014 Oct 01; 69(10):2713-22. PubMed ID: 24917579
    [Abstract] [Full Text] [Related]

  • 20. Ceftolozane/tazobactam for the treatment of complicated urinary tract and intra-abdominal infections.
    Bassetti M, Righi E.
    Future Microbiol; 2015 Oct 01; 10(2):151-60. PubMed ID: 25689527
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.